Studies of epidermal growth factor receptor inhibition in breast cancer

Endocrine-Related Cancer

Volumn 8, Issue 3, 2001, Pages 183-189

  Bundred, N J ^a   Chan, K ^a   Anderson, N G ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; FULVESTRANT; GEFITINIB; GROWTH FACTOR; ONCOPROTEIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TRASTUZUMAB;

APOPTOSIS; BREAST CARCINOMA; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER PREVENTION; CARCINOMA IN SITU; CLINICAL TRIAL; CONFERENCE PAPER; EARLY CANCER; HORMONE RESPONSE; HUMAN; NONHUMAN; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; EPITHELIAL CELLS; ESTROGEN ANTAGONISTS; ESTROGENS; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 0034795433     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0080183     Document Type: Conference Paper

References (38)

1. ZD 1839 (Iressa) a novel epidermal growth factor receptor tyrosine kinase inhibitor potently inhibits the growth of EGFR positive tumours
2. Type I receptor tyrosine kinases as targets for therapy in breast cancer
3. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumour types: Evidence of activity and good tolerability
4. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
5. The pathology of ductal carcinoma in situ of the breast
6. Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation
7. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD 1839 ('Iressa'), a selective epidermal growth factor receptor tyrosine kinase inhibitor
8. Dissociation between steroid receptor expression and cell proliferation in the human breast
9. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
10. Signal transduction in mammary tumorigenesis: A transgenic perspective
11. Interaction of the neu/p185 and EGF receptor tyrosine kinases: Implications for cellular transformation and tumor therapy
12. Incidence of and treatment for ductal carcinoma in situ of the breast
13. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
14. Intermittent oral ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: Final results from a Phase I study
15. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
16. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
17. Effects of a pure antiestrogen on apoptosis and proliferation within human breast ductal carcinoma in situ
18. The EGFR-selective tyrosine kinase inhibitor ZD 1839 ('Iressa') is an effective inhibitor of tamoxifen-resistant breast cancer growth
19. Radiotherapy and tamoxifen following complete local excision (CLE) in the management of ductal carcinoma in situ (DCIS): Preliminary results from the UK DCIS trial
20. Epidermal growth factor receptor and c-erbB-2 expression in normal breast tissue during the menstrual cycle
21. A phase I dose-escalation, pharmacokinetic (PK) and pharmacodynamic (PD) study of ZD1839 ('Iressa')' NCIC-CTG INDA22
22. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
23. Distribution and patterns of staining of Neu oncogene product in benign and malignant breast diseases
24. Assessment of hormone dependence of comedo ductal carcinoma in situ of the breast
25. The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone
26. Enhanced epidermal growth factor receptor signaling in mcr7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex)
27. Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity
28. Final results of a Phase I intermittent dose-escalation trial of ZD1839 ('Iressa') in Japanese patients with various solid tumors
29. c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma
30. Duct carcinoma in situ: Predictors of local recurrence and progression in patients treated by surgery alone
31. Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer
32. Transactivation of the EGF receptor mediates IGF-I-stimulated shc phosphorylation and ERK1/2 activation in COS-7 cells
33. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: Implications for human breast cancer
34. Ductal carcinoma in situ of the breast
35. Signal transduction by receptors with tyrosine kinase activity
36. EGF receptor
37. ZD 1839 ('Iressa') a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): Inhibition of c-fos mRNA, an intermediate marker of EGFR activation, correlates with tumor growth inhibition
38. EGF receptor tyrosine kinase inhibitors as anti-cancer agents - Preclinical and early clinical profile of ZD 1839